<DOC>
	<DOCNO>NCT00158899</DOCNO>
	<brief_summary>The purpose clinical research study compare 3 dos investigational drug GW501516 placebo ( inactive pill look like GW501516 ) see safe , well tolerate effective improving ( raise ) low level `` good cholesterol '' , high-density lipoprotein cholesterol ( HDLc ) , compare placebo .</brief_summary>
	<brief_title>GW501516 In Subjects Who Have Low Level Of High-Density Lipoprotein Cholesterol</brief_title>
	<detailed_description>A multicentre , two-staged interim analysis , parallel , randomise , double blind , placebo-controlled , dose-ranging study safety , tolerability , effect plasma high-density lipoprotein cholesterol ( HDLc ) 12 week treatment 2.5mg , 5mg 10mg daily dos GW501516 subject low HDLc</detailed_description>
	<mesh_term>Dyslipidemias</mesh_term>
	<criteria>Inclusion criterion : Have fast plasma HDLc concentration &lt; =45mg/dL ( &lt; =1.16mmol/L ) , plasma LDLc level require treatment accord National Cholesterol Education Program/Adult Treatment Panel III ( NCEP/ATPÃ‚ III ) guideline . Have fast plasma TG concentration =500mg/dL ( =5.65mmol/L ) . Exclusion criterion : Coronary heart disease . Diabetes mellitus . Atherosclerotic disease .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>HDLc</keyword>
	<keyword>high-density lipoprotein</keyword>
	<keyword>Dyslipidemia</keyword>
</DOC>